GB2346146A - Calcineurin-dependent control of skeletal muscle fiber type - Google Patents

Calcineurin-dependent control of skeletal muscle fiber type

Info

Publication number
GB2346146A
GB2346146A GB0011719A GB0011719A GB2346146A GB 2346146 A GB2346146 A GB 2346146A GB 0011719 A GB0011719 A GB 0011719A GB 0011719 A GB0011719 A GB 0011719A GB 2346146 A GB2346146 A GB 2346146A
Authority
GB
United Kingdom
Prior art keywords
skeletal muscle
present
calcineurin
muscle fiber
fiber type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0011719A
Other versions
GB0011719D0 (en
Inventor
R Sanders Williams
Eric N Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of GB0011719D0 publication Critical patent/GB0011719D0/en
Publication of GB2346146A publication Critical patent/GB2346146A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)

Abstract

The present invention relates to skeletal muscle fiber composition. More particularly, the present invention defines the molecular events linking calcium stimulation to specialization of skeletal muscle fibers. More specifically, the present invention shows that Ca<SP>2+</SP> stimulation of the slow fiber phenotype is mediated through a calcineurin-dependent pathway. Thus, the present invention provides methods and compositions for altering and/or regulating the phenotype of muscle. Further provided are methods for the detection of compounds having therapeutic activity toward regulating muscle fiber composition.
GB0011719A 1998-08-14 1999-08-13 Calcineurin-dependent control of skeletal muscle fiber type Withdrawn GB2346146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9663198P 1998-08-14 1998-08-14
PCT/US1999/018439 WO2000009667A1 (en) 1998-08-14 1999-08-13 Calcineurin-dependent control of skeletal muscle fiber type

Publications (2)

Publication Number Publication Date
GB0011719D0 GB0011719D0 (en) 2000-07-05
GB2346146A true GB2346146A (en) 2000-08-02

Family

ID=22258307

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0011719A Withdrawn GB2346146A (en) 1998-08-14 1999-08-13 Calcineurin-dependent control of skeletal muscle fiber type

Country Status (3)

Country Link
AU (1) AU5483599A (en)
GB (1) GB2346146A (en)
WO (1) WO2000009667A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629308B2 (en) 2000-07-07 2009-12-08 Board Of Regents, The University Of Texas System Methods relating to muscle selective calcineurin interacting protein (MCIP)
US6828149B2 (en) 2002-06-20 2004-12-07 Isis Pharmaceuticals, Inc. Antisense modulation of PPP3R1 expression
EP1971401A2 (en) * 2005-12-22 2008-09-24 EMBL (European Molecular Biology Laboratory) METHODS OF USING THE CALCINEURIN A VARIANT Cnaß1
CN112195254A (en) * 2020-10-30 2021-01-08 天津农学院 Method for interfering MSTN cattle skeletal muscle satellite cell real-time fluorescence quantitative PCR (polymerase chain reaction) reference gene screening

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352595A (en) * 1991-09-03 1994-10-04 Fred Hutchinson Cancer Research Center Myod regulatory region
WO1995012979A1 (en) * 1993-11-08 1995-05-18 The University Of Southern California Compositions and methods for transduction of cells
WO1998033887A1 (en) * 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352595A (en) * 1991-09-03 1994-10-04 Fred Hutchinson Cancer Research Center Myod regulatory region
WO1995012979A1 (en) * 1993-11-08 1995-05-18 The University Of Southern California Compositions and methods for transduction of cells
WO1998033887A1 (en) * 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genome Res. Vol. 7 (9) 1997. Kambadur et.al. pages 910-916 *
Mammalian Genome Vol. 9 (3) 1998. Grobet et.al. pages 210-213 *

Also Published As

Publication number Publication date
AU5483599A (en) 2000-03-06
WO2000009667A1 (en) 2000-02-24
GB0011719D0 (en) 2000-07-05
WO2000009667A9 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
MX9701679A (en) Piperidine derivatives as neurokinin antagonists.
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
ATE259215T1 (en) COMPOSITION FOR REGULATING SKIN APPEARANCE
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
CA2153869A1 (en) Powder Bleaching Compositions for Hair and Method of Use Thereof
ES2124479T3 (en) BIOCIDAL COMPOSITIONS.
BG104247A (en) Resorcinol derivatives
BG102872A (en) 6-phenylpyridyl-3-amine derivatives
PL344012A1 (en) Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
AU6794700A (en) Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
EP1027056A4 (en) Alpha-ketoamide multicatalytic protease inhibitors
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
MX9804588A (en) Use of halogen bleach-comprising compositions for improved mildness to the skin.
BG101893A (en) Nodulosporic acid derivatives
EP0831891A4 (en) Oxidant scavengers
PL328412A1 (en) Derivatives of benzamidine substituted with derivatives of amino acid and hydroxy acid as well as their application as antithrombotic agents
DE69723728D1 (en) TOTAL SYNTHESIS OF THE AMINO HIP ANALOG OF DIDEMNIN A
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
GB9712966D0 (en) Novel chalcones
GB2346146A (en) Calcineurin-dependent control of skeletal muscle fiber type
BR9611472A (en) Sulfur-containing di-tert-butylphenol compounds useful as anti-inflammatory agents
ATE217191T1 (en) USE OF PHANQUINONE TO TREAT ALZHEIMER&#39;S DISEASE

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)